Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31240235 | 0.98 | TDP1 (0.53) | TDP1EPHX2GPR84FFAR1FFAR4 | |
| SCHEMBL17296020 | 0.98 | TDP1 (0.53) | TDP1EPHX2GPR84FFAR1FFAR4 | |
| SCHEMBL16323750 | 0.98 | TDP1 (0.53) | TDP1EPHX2GPR84FFAR1FFAR4 | |
| SCHEMBL8507410 | 0.98 | TDP1 (0.53) | TDP1EPHX2GPR84FFAR1FFAR4 | |
| SCHEMBL3988979 | 0.98 | TDP1 (0.53) | TDP1EPHX2GPR84FFAR1FFAR4 | |
| SCHEMBL25168218 | 0.98 | TDP1 (0.53) | TDP1EPHX2GPR84FFAR1FFAR4 | |
| SCHEMBL16719229 | 0.98 | TDP1 (0.53) | TDP1EPHX2GPR84FFAR1FFAR4 | |
| SCHEMBL8033386 | 0.98 | TDP1 (0.53) | TDP1EPHX2GPR84FFAR1FFAR4 | |
| SCHEMBL22029385 | 0.98 | TDP1 (0.53) | TDP1EPHX2GPR84FFAR1FFAR4 | |
| SCHEMBL2099463 | 0.98 | TDP1 (0.53) | TDP1EPHX2GPR84FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298743-B1 | 5-membered heterocycle-based P38 kinase inhibitors | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | claimed |
| JP-4838121-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| EP-2298743-A1 | 5-membered heterocycle-based P38 kinase inhibitors | Novartis AG (CH) | 2011-03-23 | — | — | EP | claimed |
| JP-2007521278-A | — | — | 2007-08-02 | — | — | JP | claimed |
| EP-1641764-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | Novartis AG (CH) | 2006-04-05 | — | — | EP | claimed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | claimed |
| WO-2005009973-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-03 | — | — | WO | claimed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250197410-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4501327-A2 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON S TYROSINEKINASE (BTK) DEGRADERS | Accutar Biotechnology Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12180217-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2002057298-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002042275-A1 | 2-ARYL-5-TRIFLUOROMETHYLPYRIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |
| WO-2001087863-A1 | 3-ARYLISOTHIAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001049668-A2 | 4-ARYL-1-DIFLUOROMETHOXYIMIDAZOLES AND USE THEREOF AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-12 | — | — | WO | disclosed |
| EP-1091930-A1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001666-A1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | TDP1 1097/4885EPHX2 1923/4885GPR84 2117/4885 |
| US-12180217-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TDP1 2024/4885EPHX2 1744/4885GPR84 3439/4885 |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TDP1 2024/4885EPHX2 1744/4885GPR84 3439/4885 |
| US-20250197410-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TDP1 2024/4885EPHX2 1744/4885GPR84 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.